Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>

Saved in:
书目详细资料
主要作者: Ulka N. Vaishampayan (15051039) (author)
其他作者: Archana Thakur (15051042) (author), Wei Chen (15051045) (author), Abhinav Deol (15051048) (author), Meera Patel (15051051) (author), Kimberlee Dobson (15051054) (author), Brenda Dickow (15051057) (author), Dana Schalk (15051060) (author), Amy Schienschang (15051063) (author), Sarah Whitaker (15051066) (author), Amanda Polend (15051069) (author), Joseph A. Fontana (411960) (author), Elisabeth I. Heath (15024674) (author), Lawrence G. Lum (15051072) (author)
出版: 2025
主题:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Genitourinary Cancers
Prostate cancer
Immunotherapy
Cellular immunotherapy
标签: 添加标签
没有标签, 成为第一个标记此记录!
实物特征
总结:<p>Shows the persistence of anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) in the peripheral blood of two out of four patients.</p>

相似书籍